Your session is about to expire
← Back to Search
ViviGen Cellular Bone Matrix for Spondylolisthesis
Study Summary
This trial is testing a new way to fuse the spine in one or multiple levels. All subjects will be followed for 24 months.
- Spondylolisthesis
- Degenerative Disc Disease
- Spondylosis
- Spinal Stenosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA approved ViviGen Cellular Bone Matrix for clinical use?
"ViviGen Cellular Bone Matrix has achieved a score of 3 on our team's risk scale since it is in its fourth phase of testing, which implies full approval."
Is recruitment currently underway for this clinical trial?
"Affirmative. The clinicaltrial.gov page demonstrates that the trial is actively enrolling participants, having first been posted on February 12th 2019 and most recently updated on October 25 2021. This study looks to recruit 50 patients at a single site."
How many individuals are being recruited into this research project?
"Affirmative. According to clinicaltrials.gov, this investigation is at present recruiting subjects. It was initially posted on February 12th 2019 and amended on October 25th 2021; it aims to enlist 50 participants from one single medical site."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger